Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Prostatic Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Metastatic Hormone-sensitive Prostate Cancer 2Non-metastatic, Hormone naïve Prostate Cancer 1Metastatic Hormone Sensitive Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Hormone Sensitive Prostate Cancer 1Adenocarcinoma of the Prostate 1

Interventions

pembrolizumab 120Cisplatin 26Carboplatin 24Paclitaxel 21Docetaxel 17lenvatinib 15Pemetrexed 12Fluorouracil 12Saline Solution 11Capecitabine 10epacadostat 8Oxaliplatin 7Gemcitabine 7Leucovorin 5Cetuximab 5130-nm albumin-bound paclitaxel 5olaparib 4enzalutamide 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3Prednisone 3Dexamethasone 3Radiotherapy 2Ipilimumab 2Glucose 2Etoposide 2Doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Parkinson Disease 4, Autosomal Dominant Lewy Body × Androgen Antagonists × Clear all
NCT04191096 2026-04-29

KEYNOTE-991

Merck Sharp & Dohme LLC

Phase 3 Completed
1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04934722 2025-10-01

KEYNOTE-991

Merck Sharp & Dohme LLC

Phase 3 Completed
186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

Data powered by HemOnc (CC BY 4.0) Colophon âš¡